{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:28:18Z","timestamp":1778290098267,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00223-018-0389-1","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T06:37:36Z","timestamp":1517553456000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-7264","authenticated-orcid":false,"given":"Liana","family":"Tripto-Shkolnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rouach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonit","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pnina","family":"Rotman-Pikielny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Benbassat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Vered","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"389_CR3","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR et al (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832\u20131841. \n                    https:\/\/doi.org\/10.1359\/jbmr.070809","journal-title":"J Bone Miner Res"},{"key":"389_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR (2006) Denosumab in postmenopausal women with low bone mineral density. New Engl J Med 354:821\u2013831. \n                    https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"New Engl J Med"},{"key":"389_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. \n                    https:\/\/doi.org\/10.1210\/jc.2010","journal-title":"J Clin Endocrinol Metab"},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, T\u00f6rring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 28:746\u2013752. \n                    https:\/\/doi.org\/10.1002\/jbmr.1808","journal-title":"J Bone Miner Res"},{"key":"389_CR7","doi-asserted-by":"publisher","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D et al (2016) Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab 2016\u20133170. \n                    https:\/\/doi.org\/10.1210\/jc.2016-3170","DOI":"10.1210\/jc.2016-3170"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"key":"389_CR9","doi-asserted-by":"publisher","unstructured":"Polyzos SA, Terpos E (2016) Clinical vertebral fractures following denosumab discontinuation. Endocrine 271\u2013272. \n                    https:\/\/doi.org\/10.1007\/s12020-016-1030-6","DOI":"10.1007\/s12020-016-1030-6"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"389_CR11","doi-asserted-by":"publisher","unstructured":"Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 1929\u20131930. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3459-5","DOI":"10.1007\/s00198-015-3459-5"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","volume":"27","author":"MR McClung","year":"2016","unstructured":"McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27:1677\u20131682. \n                    https:\/\/doi.org\/10.1007\/s00198-016-3553-3","journal-title":"Osteoporos Int"},{"key":"389_CR13","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1210\/jc.2016-3781","volume":"102","author":"G Trovas","year":"2017","unstructured":"Trovas G (2017) Letter to the editor: severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab 102:3781. \n                    https:\/\/doi.org\/10.1210\/jc.2016-3781","journal-title":"J Clin Endocrinol Metab"},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P et al (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683. \n                    https:\/\/doi.org\/10.1530\/EJE-16-1027","journal-title":"Eur J Endocrinol"},{"key":"389_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296. \n                    https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28:2701\u20132705. \n                    https:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporos Int"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.maturitas.2017.04.016","volume":"102","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P (2017) Bisphosphonates or denosumab discontinuation and risk of fractures. Maturitas 102:75. \n                    https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.016","journal-title":"Maturitas"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. \n                    https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"389_CR19","first-page":"1352","volume":"68","author":"JP Brown","year":"2016","unstructured":"Brown JP, Ferrari S, Gilchrist N et al (2016) Discontinuation of denosumab and associated vertebral fracture incidence: analysis from a phase 3 placebo-controlled study of denosumab and its open-label extension. Arthritis Rheumatol 68:1352\u20131353","journal-title":"Arthritis Rheumatol"},{"key":"389_CR20","first-page":"217","volume":"27","author":"AT Trout","year":"2006","unstructured":"Trout AT, Kallmes DF, Kaufmann TJ (2006) New fractures after vertebroplasty: adjacent fractures occur significantly sooner. Am J Neuroradiol 27:217\u2013223","journal-title":"Am J Neuroradiol"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00198-008-0745-5","volume":"20","author":"A Mudano","year":"2009","unstructured":"Mudano A, Bian J, Cope J et al (2009) Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. Osteoporos Int 20:819\u2013826. \n                    https:\/\/doi.org\/10.1007\/s00198-008-0745-5","journal-title":"Osteoporos Int"},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0389-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T20:02:05Z","timestamp":1549051325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0389-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0389-1","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"24 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Tripto-Shkolnik reports personal fees from AMGEN, personal fees from ELI LILLY, outside the submitted work. Dr. Rouach reports personal fees from AMGEN, personal fees from ELI LILLY, outside the submitted work. Dr. Marcus has nothing to disclose. Dr. Rotman-Pikielny reports personal fees from AMGEN, personal fees from ELI LILLY, outside the submitted work. Dr. Benbassat has nothing to disclose. Dr. Vered reports personal fees from AMGEN, personal fees from ELI LILLY, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}